BioCryst Completes $700M Astria Deal, Cramer Urges Investors to Avoid Stock
Jim Cramer advised investors to stay away from BioCryst Pharmaceuticals, calling it a “very bad stock” with limited prospects despite recent price gains. On January 23 the company finalized its $700 million acquisition of Astria Therapeutics, adding Phase 3 therapy navenibart for hereditary angioedema to its rare disease portfolio.
1. Cramer’s Cautionary Stance
Jim Cramer told viewers they should steer clear of BioCryst, characterizing its share performance as poor and unlikely to improve despite a recent 2.2% uptick.
2. Operations and Pipeline
BioCryst develops rare disease treatments, including the oral hereditary angioedema drug berotralstat and an injectable influenza therapy, while advancing new candidates for allergic and immunological disorders.
3. Astria Acquisition Bolsters HAE Portfolio
On January 23 BioCryst closed its $700 million deal for Astria Therapeutics, acquiring navenibart, a long-acting Phase 3 therapy for hereditary angioedema, to reinforce its leadership in rare swelling disorders.